Form 4: Gossamer Bio's Chief Medical Officer Acquires 572,000 Stock Options

Richard Aranda, Chief Medical Officer of Gossamer Bio, Inc., reports the acquisition of 572,000 stock options on March 4, 2025.

Summary

• Richard Aranda, the Chief Medical Officer of Gossamer Bio, Inc., filed a Form 4 with the SEC.
• The filing reports a transaction that occurred on March 4, 2025, where Aranda acquired 572,000 stock options.
• These options have an exercise price of $1.13.
• The options vest over time, with 25% vesting on March 4, 2026, and the remainder vesting monthly thereafter, contingent upon continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, suggesting confidence from the executive in the company's future.

Positives

• The acquisition of stock options by a key executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule indicates a long-term commitment from the Chief Medical Officer to the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• The vesting schedule of these options is fairly standard, with an initial cliff followed by monthly vesting.
• Comparing the size of the grant to similar companies would require analyzing Gossamer Bio's compensation strategy relative to its peers.

Stakeholder Impact

• The stock option grant aligns the executive's interests with those of shareholders, potentially driving long-term value creation.

Key Dates